Private company

European Biotech Acquisition Corp.

Blank check company based in Amsterdam, Cayman Islands2

In its 2023 annual report the company says: “We are a blank check company incorporated on January 8, 2021 as a Cayman Islands exempted company formed for the purpose of effecting a Business Combination.”26

Last updated Oct 20, 2026.

Overview

$342.9KNet income, fiscal 20223
  • IndustryBlank Checks2
  • HeadquartersAmsterdam, Netherlands2
  • Incorporated inCayman Islands4
  • Business addressEpfl Innovation Park Building, Lausanne, V8 10154
  • Filer category, Emerging growth company4
  • Legal formexempt company2
  • LEI984500Y57CDE4CE7CC202
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressP. O. Box 309, KY1-1104 George Town, Cayman Islands2
  • Registered withGeneral Registry, 3699392

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$2.8M in 2022+156% since 2021
-$3.0M-$2.0M-$1.0M02021: -$1.1M-$1.1M20212022: -$2.8M-$2.8M2022+156%
Net income3$342.9K in 2022−77% since 2021
0$500.0K$1.0M$1.5M2021: $1.5M$1.5M20212022: $342.9K$342.9K2022−77%
Fiscal year20212022
Operating income-$1.1M3-$2.8M3
Income before tax$1.5M3$342.9K3
Net income$1.5M3$342.9K3

Compare European Biotech Acquisition Corp. with another company

Corporate structure

European Biotech Acquisition Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of European Biotech Acquisition Corp.

  • GLAZER CAPITAL, LLC Filed SC 13G on European Biotech Acquisition Corp., latest Feb 14, 2023
  • PERISCOPE CAPITAL INC. Filed SC 13G on European Biotech Acquisition Corp., latest Feb 13, 2023
  • INTEGRATED CORE STRATEGIES (US) LLC Filed SC 13G/A on European Biotech Acquisition Corp., latest Feb 6, 2023 (2 filings since Jan 27, 2022)
  • CITADEL ADVISORS LLC Filed SC 13G/A on European Biotech Acquisition Corp., latest Feb 14, 2022
  • Sponsor Ebac B.v. Lsp Filed SC 13G on European Biotech Acquisition Corp., latest Feb 8, 2022
  • European Biotech Acquisition Corp. Amsterdam, Netherlands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What European Biotech Acquisition Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$308.5K3 Dec 31, 2022$868.3K3 Dec 31, 2021−64.5%

Leadership

Who has led European Biotech Acquisition Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. De Araoz Eduardo Bravo Fernandez2021

Chief financial officer

  1. Koen Sintnicolaas2021
2025
Board members and other officers (4)

Timeline

  1. Feb 28, 20238-K Executive or director change; Shareholder vote; Other events14
  2. Feb 21, 20238-K New debt or obligation15
  3. Feb 14, 20238-K New debt or obligation16
  4. Jan 30, 20238-K Entered a material agreement17
  5. Dec 14, 20228-K Regulation FD disclosure18
  6. Oct 17, 20228-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure19
  7. Nov 23, 20218-K Earlier financial statements no longer reliable20
  8. Mar 15, 2021New chief executive De Araoz Eduardo Bravo Fernandez becomes CEO8

Filings

25 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 7 major events, 6 large holders, 6 other. The latest 20:

  1. Mar 13, 202315-12G EDGAR
  2. Feb 28, 20238-K EDGAR
  3. Feb 28, 202310-K EDGAR
  4. Feb 21, 20238-K EDGAR
  5. Feb 14, 20238-K EDGAR
  6. Feb 14, 2023DEFA14A EDGAR
  7. Feb 14, 2023SC 13G EDGAR
  8. Feb 13, 2023SC 13G EDGAR
  9. Feb 6, 2023SC 13G/A EDGAR
  10. Feb 3, 2023DEFM14A EDGAR
  11. Jan 30, 2023425 EDGAR
  12. Jan 30, 20238-K EDGAR
  13. Dec 14, 2022425 EDGAR
  14. Dec 14, 20228-K EDGAR
  15. Nov 14, 202210-Q EDGAR
  16. Oct 17, 20228-K EDGAR
  17. Aug 15, 202210-Q EDGAR
  18. May 16, 202210-Q EDGAR
  19. Mar 31, 202210-K EDGAR
  20. Feb 14, 2022SC 13G/A EUROPEAN BIOTECH ACQUISITION CORP. EDGAR

The 25 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How European Biotech Acquisition Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREuropean Biotech Acquisition Corp.1
  • CIK0001841258
  • Filer status<br>emerging growth company1
  • Incorporated inCayman Islands1
  • Fiscal year endsDecember 311
  • Industry code (SIC)6770 Blank Checks1
  • Business addressEpfl Innovation Park Building, Lausanne, V8 10151
  • Phone41 77 976 21 091
  • Public float$129.2M as of Jun 30, 20223
  • On EDGAR sinceFeb 5, 20211
  • Filings65 in all: 8-K (12), 3 (8), 10-Q (6), SC 13G (5), UPLOAD (5), S-1/A (4), CORRESP (3), NT 10-Q (3)1
    All 23 form types

    SC 13G/A (3), 10-K (2), 425 (2), 15-12G (1), 25-NSE/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEFA14A (1), DEFM14A (1), DRS (1), EFFECT (1), F-4 (1), S-1 (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2023
    Quarterly report (10-Q) Nov 14, 2022
    Latest 8-K (8-K) Feb 28, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26